PIN+sintilimab
Phase 1Monoclonal antibody
Novo NordiskPIN+sintilimab is one of 7 biologic programs targeting Metastases. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Metastases
#DrugCompanyPhaseTrials
1Opdivo
Bristol-Myers SquibbPhase 2
Erleada
Johnson & JohnsonPhase 2
Androgen Deprivation Therapy
Johnson & JohnsonPhase 2
Adriamycin
PfizerPhase 1
AU-011
AAura Biosciences
Phase 2
Lymphazurin
CCovidien
Preclinical
PIN+sintilimab
Novo NordiskPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metastases1 trial
PIN in Combination With Sintilimab in Previously Treated pMMR/MSS CRC With Hepatic Metastases
Not yet recruiting·—·Phase 1·NCT07411781·25 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PIN+sintilimab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 1[1]
- Company